KEAP1 and leukemia: Moreover, treatment with venetoclax/HMA reversed decitabine-induced nuclear translocation of NRF2, expression of downstream antioxidant enzymes and BCL2-binding to NRF2/kelch-like ECH-associated protein 1 (KEAP-1) complex, resulting in an anti-leukemia activity [94].